Research : Musculoskeletal Oncology

Musculoskeletal Oncology Signal Transduction Laboratory

Dr. Karina Galoian, along with Dr. H. Thomas Temple, professor emeritus, established the Musculoskeletal Oncology Signal Transduction Laboratory. Dr. Galoian earned her Master’s Degree in Biological Sciences from the University of Armenia in May 1981, and a Master’s Degree and Ph.D. in Biochemistry from the National Academy of Sciences of Armenia in 1983 and 1986 respectively. In 1993-1995 she was a Fogarty International Visiting fellow in pharmacology at the National Institutes of Mental Health in Bethesda, MD. Dr. Galoian completed her postdoctoral fellowship at the University of Pennsylvania where she investigated leukemogenic fusion proteins occurring during chromosomal translocation. Her scientific interest focuses on investigating the molecular mechanisms involved in malignant transformation. She currently holds the position of Research Associate Professor and heads the Departmental Institutional Review Board at the University of Miami, Miller School of Medicine in the Department of Orthopaedics. Dr Galoian is Research Director of Sarcoma Disease Site Group at the Sylvester Comprehensive Cancer Center. She continues to pursue cancer research focusing on the study of molecular pathways leading to malignant transformation and molecular signatures, defining normal chondrogenesis versus sarcomagenesis. The main focus of Dr. Galoian’s lab work is to develop a combined treatment protocol leading to sarcoma cure and studying in depth very promising antitumorigenic derivatives of hypothalamic neuropeptides.

Sarcomas and chondrosarcomas result from the unregulated growth of mesenchymal stem cells. One of the areas of concern with these sarcomas is that they do not appear to respond either to chemotherapy or radiation, leaving surgical resection as the only option. Effective adjuvant therapy for this malignant metastatic disease is urgently needed. The primary interest of the laboratory is elucidation of signal transduction pathways involved in musculoskeletal tumors progression and metastasis, mechanisms of cellular cancer dormancy, cell cycle and oncogene inactivation and extracellular matrix-cell communications. A significant problem for translational research is cancer recurrence and drug resistance. Another focus of the laboratory is exploring the involvement of the mitogen activated protein kinase (MAPK) feedback loops and mediated cytoskeletal events in drug resistance.

Dr. Galoian’s work has been presented on the local, national, and international levels. Additionally, Dr. Galoian has authored and co-authored many publications in journals such as Cancer Cell and Blood. She also serves as a scientific reviewer for articles under consideration for publication in prestigious U.S. and international journals.

Podium presentations

American Association of Orthopaedic Surgeons, American and International Research Societies of Orthopaedics, American and Canadian Orthopaedic Societies, American and International Societies of Neurochemistry, American Society of Hematology ,Connective Tissue Oncology Society, Spandidos Conferences.

Galoian, K.A., Ronde P., Snyder D. and Nichols R., Measurement in Ca levels changes in the cardiac Nerve terminals using confocal microscopy. J. of Neurochem. Supp. Abstracts v. 69, ISN/ASN meeting Boston, MA, July 1997. (Same material was introduced as oral and one of the best presentations from stage at 3rd Advanced School of Neurochemistry in Amherst College, Amherst, MA July 16-19, 1997) (Podium).

Galoian, K.A. Milne T, Brock H, Shilatifard A, Slany R, Hess J. Deregulation of c-MYC by leukemogenic MLL Fusion proteins. BLOOD, v.96, n 11 Nov.16, 2000 p.457 (a). Material was introduced as podium presentation at the 42nd Annual Meeting of American and International Societies of Hematology in San-Francisco, CA December 1-5(Podium).

Galoian, K.A., Garamszegi N., Garamszegi S. and S. Scully Molecular Mechanism of Tenascin C Action on Martix Metalloproteinase- 1 Invasive Potential 6th Combined International meeting of Orthopedic Research Societies, October 20-25, 2007, Honolulu, Hawaii. Presented at COA/AOA Societies meeting June 4-7, 2008 Quebec City, QB, Canada (Podium).

Galoian, K.A. H.T. Temple, Galoyan A.A., Cytostatic effect of the hypothalamic cytokine PRP-1 is mediated by mTOR and cMyc inhibition in high grade metastatic chondrosarcomas. AAOS meeting February 15-18, 2011, San Diego, CA (Podium).

Galoian, K.A. H.T. Temple HDAC inhibitor Panobinostat (LBH589) effect on mesenchymal tumors and chordomas. Connective Tissue Oncoloy Society 17th annual meeting. November 14-17, Prague, Czech Republic (Podium discussion).

Galoian, K.A., H.T. Temple mTORC1 inhibitor targets Src oncogenic pathway by upregulating HSA miR99A, 450A and 199B-5P in human chondrosarcoma. Connective Tissue Oncology Society 17th annual meeting, November 14-17, 2012, Prague, Czech Republic (Podium discussion).

Galoian K., Guettouche T, Issac B, Qureshi A, Temple H.T. Regulation of onco and tumor suppressor miRNAS by MTORC1 inhibitor PRP-1 un human chondrosarcoma, (poster ) Miami Winter symposium (UM and Elseviers Publishers) January Towards Personalized Medicine in Cancer, 2015.

Galoian K. , Qureshi A, Temple H.T. Targeting Cancer Stem Cell Marker miR302C in Human Chondrosarcoma Determines the Antiproliferative Activity of Proline Rich Polypeptide1.Poster session : PS2-174 ,: Cancer, Tumors poster number : 1946;ORS annual Meeting, March 28-31. Las Vegas, Nevada, 2015.

Galoian K., et al,: Epigenetic regulation of embryonic stem cell marker mir302c in human chondrosarcoma as determinant of antiproliferative activity of proline rich polypeptide 1 and Treatment with a small molecule IDH1 inhibitor suppresses tumorigenic activity and decreases production of the oncometabolite 2-hydroxyglutarate in IDH1- mutant human chondro-sarcoma cells” AACR Basic Science of sarcoma conference and CTOS November 3-8, Salt Lake city, Utah 2015.

Galoian K., Qureshi A, Wideroff G, Temple H,T. Restoration of desmosomal junction protein expression and inhibition of H3K9 specific histone demethylase activity by cytostatic, PRP-1 leads to suppression of tumorigenic potential in human chondrosarcoma cells. 20th Congress on Advances in Oncology and 18th International symposium on Molecular Medicine (Podium Speaker), Athens, Greece, 2015. Published in International Journal of Molecular Medicine v 36, Supplement 1, 2015.

Galoian K., Luo S, Qureshi A, Price,R ,Morse, A.S, Temple H.T. Effect of cytostatic prp-1 on socs3 and interleukin6 mediated inflammatory signaling in chondrosarcoma Miami Winter symposium (Nature Elsevier , University of Miami,) Hyatt Regency 24-28 January, 2016.

Orthopaedic Research Society meeting, Orlando, Florida, November 5-8, 2016.

Recent posters

Galoian, K.A, Garamszegi N, Garamszegi S, and Scully S. Molecular Mechanism of Tenascin C -1 Invasive Potential on Matrix Metalloproteinase -1 invasive potential. 14th Meeting of Connective Tissue Oncology Society meeting, London, UK, November 13-15, 2008.

Galoian, K.A, Scully S.P, Galoyan A.A Antitumorigenic properties of hypothalamic PRP-1 peptide in chondrosarcoma. 15th Meeting of Connective Tissue Oncology Society meeting, Miami Beach , FL, 2009; and Miami Winter Symposium Targeting Cancer Invasion and Metastasis, Miami Beach, FL, 2010.

Galoian, K.A, Temple H.T, Galoyan A.A. Cytostatic effect of the hypothalamic cytokine PRP-1 is mediated by its inhibition of mTOR and cMyc in high grade metastatic chondrosarcoma. 16th Meeting of Connective Tissue Oncology Society, Paris, France, 2010.

Galoian, K.A, Temple HT. ECM-cell adhesion independent drug resistance in chondrosarcoma is mediated by GSK3beta inactivation Combined CTOS/MSTS Meeting, Chicago, IL, October 26-29, 2011.

Galoian, K.A, T. Guettouche, B.Issac ,L. Navarro and H.T. Temple. Lost miRNA surveillance of Notch, IGFR pathway- road to sarcomagenesis.Tumor Biology, 2013 Accepted, 18th CTOS annual meeting New York City , USA
Karina Galoian, PhD, Toumy Guettouche, Biju Issac, Amir Qureshi, H.T. Temple Regulation of onco and tumor suppressor miRNAS by MTORC1 inhibitor PRP-1 un human chondrosarcoma. CTOS meeting, October 15-18, 2014, Berlin, Germany.

Luyuan Li, AnnaPaz Mejia, Britt Johnson, Karina Galoian, PhD., Breelyn A. Wilky, MD, Andrew E. Rosenberg, Olaf Bodamer, Jonathan C. Trent. Evaluation of IDH mutation, IDH 1 inhibition and 2-hydroxyglutarate in human chondrosarcoma cell lines and patients plasma. CTOS meeting, October 15-18, 2014, Berlin, Germany.

Karina Galoian, PhD, Amir Qureshi, MD, H. T. Temple, MD Targeting Cancer Stem Cell Marker miR302C in Human Chondrosarcoma Determines the Antiproliferative Activity of Proline Rich Polypeptide 1 Cancer Tumors POSTER #:1946 ORS Annual Meeting, March 28-31. Las Vegas, Nevada, 2015.

Karina Galoian, PhD, Toumy Guettouche, Biju Issac, Amir Qureshi, H. T. Temple Regulation of onco and tumor suppressor miRNAS by MTORC1 inhibitor PRP-1 un human chondrosarcoma, (poster) Miami Winter symposium 2015, (UM and Elseviers Publishers) January Towards Personalized Medicine in Cancer.

Peer–reviewed publications

Venkataraman V, Duda T, Galoian KA, Sharma R. Molecular and pharmacological identity of alpha 2D adrenergic receptor in bovine retina and its photoreceptors. Mol. and Cell. Biochem. 159:129-138,1996.

Aprikian VS, Galoian KA, Galoyan AA. Influence of hypothalamic polypeptides on cell mediated immune response. Neirokhimiya 15:182-195, 1998.

Galoian KA. Measurement of changes in calcium levels in isolated cardiac nerve terminals using confocal microscopy. Neirokhimiya. 15: 373-379., 1998.

Galoian KA, Milne T, Brock H, Shilatifard A, Slany R, Hess J. Deregulation of c-MYC by leukemogenic MLL Fusion proteins. BLOOD, v.96, n 11 Nov.16. p.457( a ), 2000.

Martin M, Milne T, Bloyer S, Galoian KA , Shen W, Gibbs D, Brock H, Slany R, Hess J. Dimerization of MLL fusion proteins immortalizes hematopoietic cells. Cancer Cell. 4:197-207, 2003.

Galoian KA, Garamszegi N, Garamszegi S, Scully S. Molecular Mechanism of Tenascin C Action on Matrix Metalloproteinase -1 Invasive Potential. Experimental Biology and Medicine. April,v.232, issue 4, 515-522, 2007.

Galoyan AA, Danielian KE, Galoian KA, Kramer A, Davtian TK, Bezirganian K, Kriegerstein J. Effect of hypothalamic neurosecretory cytokine proline rich polypeptides (PRP) on the neuronal and hematopoietic cell apoptosis. Neurochemical Research. June, 32 (11), 1898-1905, 2007.

Galoian KA, Scully SP, Galoyan AA. Myc-oncogene inactivating effect of Proline Rich Polypeptides (PRP-1) in the Human Chondrosarcoma JJ012 cells. Neurochemical Research v 34, issue 2, 379-385, 2009.

Galoian K, Scully S, McNamara G, Flynn P, Galoyan A.Antitumorigenic effect of brain Proline Rich Polypeptide-1 in Human Chondrosarcoma. Neurochemical research , vol 34, issue 12. p 2117, 2009.

Tavadyan LA, Galoian KA, Harutunyan LA, Tonikyan HG, Galoyan AA. Antioxidant and Electron Donating Function of Hypothalamic Polypeptides: Galarmin and Gx-NH(2).Neurochem Res. 35 (6):947-52, 2010 .

Felix, ER, Galoian, KA, Aarons, CE, Kearing, SA, Heiss, UE, Brown, MD: Utility of Computerized pain drawings .Pain Medicine, 11: 382-389, 2010.

Alexanyan M.K., Galoian K.A., Simonyan G.M., Stepanyan G.M., Simonyan R.M., Muradyan R.E., Alexanyan S.S., Simonyan M.A., Galoyan A.A. The increase of the NADPH depending superoxide-produsing and ferrihemoglobin-reducing activities of acidic nature isoform of cytochrome b558 from mouse sarcomas -37 tumor tissue cells under the influence of Proline-Rich Polypeptide (PRP-1) in vitro. Issues of Teoretical Klin.Med., 13(2): 54-57, 2010.

Simonyan G.M., Galoian K.A., Simonyan R.M., Simonyan M.A. and Galoyan A.A. Proline rich polypeptide increases the superoxide –producing and ferrihemoglobin reducing activities of cytochrome B558 isoforms from human lymphosarcoma tissue cells. Neurochemical research v36:739-745, 2011.

Galoian K.A, Temple H.T, Galoyan A.A. Cytostatic effect of the hypothalamic cytokine PRP-1 is mediated by its inhibition of mTOR and cMyc in high grade metastatic chondrosarcoma Neurochem Res 36:812–818, 2011.

Galoian K.A Temple H.T, Galoyan A.A . Cytostatic effect of novel mTOR inhibitor, PRP-1 in MDA231 (ER-) breast carcinoma cell line. The cytokine inhibits mesenchymal tumors Tumor Biology Aug; 32(4):745-51, 2011.

Galoian, K.A Temple H.T Galoyan, A.A mTORC 1 inhibition in chondrosarcoma and ECM- cell adhesion independent drug resistance via PI3K-AKT feedback loop. Tumor Biology, 2012 33(3):885-90, 2012.

Durgaryan AA, Matevosyan MB, Seferyan TE, Sargsyan MA, Grigoryan S, Galoian KA and Galoyan AA. The Protective and Immunomodulatory Effects of Hypothalamic Proline Rich Polypeptide Galarmin against Methicillin-Resistant Staphylococcus aureus Infection in Mice. European Journal of Clinical Microbiology & Infectious Diseases. 31(9):2153-65, 2012

K. Galoian, T. Guettouche, B.Issac ,L. Navarro and H.T. Temple. Lost miRNA surveillance of Notch, IGFR pathway- road to sarcomagenesis.Tumour Biology 35 (1) :483-492 , 2014

K. Galoian, T. Guettouche, B.Issac , A. Qureshi and H.T. Temple Regulation of onco and tumor suppressor miRNAs by mTORC1 inhibitor PRP-1 in human chondrosarcoma Tumour Biol. 35(3):2335-41, 2014

Karina Galoian, Amir Qureshi, Gina Wideroff, H.T. Temple. Restoration of desmosomal junction protein expression and inhibition of H3K9-specific histone demethylase activity by cytostatic proline-rich polypeptide-1 leads to suppression of tumorigenic potential in human chondrosarcoma cells. Molecular and Clinical Oncology 3: 171-178, 2015

B. Issac, K. Galoian, T. Guettouche, Navarro, H.T. Temple. Genome-wide mRNA and miRNA expression data anlysis to screen for markers involved in sarcomagenesis in human chondrosarcoma cell lines. Genomics Data 2:320-324, 2015

Galoian K.A,Qureshi A, Dippolito G,Schiller, P.C,Molinari M, Johnstone, A.L.Brothers,S.P Paz, A.C ,Temple H.T Epigenetic regulation of embryonic stem cell marker miR302C in human chondrosarcoma as determinant of antiproliferative activity of praline rich polypeptide 1.lnternational Journal of Oncology, 47: 465-472, 2015.

Li L, Paz AC, Wilky BA, Johnson B, Galoian K, Rosenberg A, Hu G, Tinoco G, Bodamer, Trent JC. Bodamer O. Treatment with a small molecule IDH1 inhibitor suppresses tumorigenic activity and decreases production of the oncometabolite 2-hydroxyglutarate in IDH1- mutant human chondro- sarcoma cells. PLOS One Sep 14; 10 (9):e0133813. doi: 10.1371, 2015.